Royalty Pharma announced its acquisition of royalties on Vertex Pharmaceuticals’ cystic fibrosis treatments owned by Cystic Fibrosis Foundation Therapeutics Read the full story

DRI Capital and Rush University Medical Center announced that Drug Royalty III, DRI has purchased Rush’s royalties relating to worldwide sales of Ampyra for approximately $42 million. Read the full story

Supernus Pharmaceuticals announced the execution of a royalty financing agreement with HealthCare Royalty Partners. Read the full story

A royalty created where none had previously existed. The royalty stream is generated from future sales ... Read the full story

A sale of rights to royalties for sale of the product which would have otherwise been due to the licensor... Read the full story

This article talks about the industry trend analysis of signing royalty and revenue financing deals among life science sectors Read the full story

Royalty Pharma has acquired an additional interest in the royalty financing to the former shareholders of Fumapharm AG for $510 million in cash. Read the full story

Vertex brings a long time pharma deal with Janssen to an end by sell its royalty rights on INCIVO net sales.  Read the full story

DRI Capital announced the final closing of its U.S. $1.45 billion Drug Royalty III private equity financing fund. Read the full story

Royalty Pharma has sold it's $485 million interest in Ibrutinib to Aisling Capital and Clarus Ventures in a royalty financing round. Read the full story